Characterization of 5(6)-carboxy-2,′7′-dichlorofluorescein transport by MRP2 and utilization of this substrate as a fluorescent surrogate for LTC4

Journal of Biomolecular Screening

Volumn 13, Issue 4, 2008, Pages 295-301

  Heredi Szabo, Krisztina ^a   Kis, Emese ^a   Molnar, Eva ^a   Gyorfi, Andras ^a   Krajcsi, Peter ^a  

^a SOLVO BIOTECHNOLOGY   (Hungary)

Author keywords

Fluorescence; LTC4; MRP2; Vesicular transport

Indexed keywords

4 AMINOHIPPURIC ACID; 5(6) CARBOXY 2,7 DICHLOROFLUORESCEIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BAICALEIN; BENZBROMARONE; BROMSULFOPHTHALEIN; CYCLOSPORIN A; DICHLOROFLUORESCEIN; DICLOFENAC; ESTRADIOL 17 GLUCURONIDE; FUROSEMIDE; GENISTEIN; GLIBENCLAMIDE; GLUTATHIONE; IBUPROFEN; INDOMETACIN; LEUKOTRIENE C4; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 2; OMEPRAZOLE; PARACETAMOL GLUCURONIDE; PIROXICAM; PROBENECID; RIFAMYCIN; SALAZOSULFAPYRIDINE; SULFINPYRAZONE; SULINDAC; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; VERLUKAST; XENOBIOTIC AGENT;

APICAL MEMBRANE; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL TRANSPORT; CHEMICAL INTERACTION; FLUORESCENCE; HIGH THROUGHPUT SCREENING; LIVER TOXICITY; MEMBRANE VESICLE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BIOLOGICAL TRANSPORT; FLUORESCEINS; FLUORESCENT DYES; HUMANS; KINETICS; LEUKOTRIENE C4; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; REPRODUCIBILITY OF RESULTS;

EID: 41149167209     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057108316702     Document Type: Article

References (39)

1. Glavinas H., Krajcsi P., Cserepes J., Sarkadi B.: The role of ABC transporter in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004 ; 1: 27-42.
2. Ambudkar SV, Kim IW, Sauna ZE: The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 2006 ; 27: 392-400.
3. Locher K.: Structure and mechanism of ABC transporters. Curr Opin Struct Biol 2004 ; 14: 426-431.
4. Keppler D., Konig J.: Hepatic canalicular membrane 5: expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB J 1997 ; 11: 509-516.
5. Buchler M., Konig J., Brom M., Kartenbeck J., Spring H., Horie T.,, et al. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 1996 ; 271: 15091-15098.
6. Mottino AD, Hoffman T., Jennes L., Vore M.: Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J Pharmacol Exp Ther 2000 ; 293: 717-723.
7. Van Aubel RA, Masereeuw R., Russel FG: Molecular pharmacology of renal organic anion transporters. Am J Physiol Renal Physiol 2000 ; 279: F216 - F232.
8. Jedlitschky G., Leier I., Buchholz U., Barnouin G., Keppler D.: Transport of glutathione, glucuronide and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 1996 ; 56: 988-994.
9. Dubin IN, Johnson FB: Chronic idiopathic jaundice with unidentified pigment in liver cells: a new clinicopathologic entity with report of 12 cases. Medicine 1954 ; 33: 155-179.
10. Kartenbeck J., Leuschner U., Mayer R., Keppler D.: Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 1996 ; 23: 1061-1066.
11. Nezasa K., Tian X., Zamek-Gliszczynski MJ, Patel NJ, Raub TJ, Brouwer KL: Altered hepatobiliary disposition of 5 (and 6)-carboxy-2, ′7′dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice. Drug Metab Dispos 2006 ; 34: 718-723.
12. Donner MG, Keppler D.: Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 2001 ; 34: 351-359.
13. Nies AT, König J., Pfannschmidt M., Klar E., Hofmann WJ, Keppler D.: Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 2001 ; 94: 492-499.
14. Lengyel G., Veres Z., Tugyi R., Vereczkey L., Molnár T., Glavinas H.,, et al. Modulation of sinusoidal and canalicular elimination of bilirubinglucuronides by rifampicin and other cholestatic drugs in a sandwich culture of rat hepatocytes. Hepatology Res 2008 ; 38: 300-309.
15. Bodo A., Bakos E., Szeri F., Varadi A., Sarkadi B.: Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J Biol Chem 2003 ; 278: 23529-23537.
16. Cui Y., Konig J., Keppler D.: Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol 2001 ; 60: 934-943.
17. Ito K., Suzuki H., Sugiyama Y.: Charged amino acids in the transmembrane domains are involved in the determination of the substrate specificity of rat Mrp2. Mol Pharmacol 2001 ; 59: 1077-1085.
18. Ninomiya M., Ito K., Hiramatsu R., Horie T.: Functional analysis of mouse and monkey multidrug resistance-associated protein 2 (Mrp2). Drug Metab Dispos 2006 ; 34: 2056-2063.
19. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG: Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther 2007 ; 320: 229-235.
20. Chen ZS, Kawabe T., Ono M., Aoki S., Sumizawa T., Furukawa T.,, et al. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol 1999 ; 56: 1219-1228.
21. Gao M., Yamazaki M., Loe DW, Westlake CJ, Grant CE, Cole SP,, et al. Multidrug resistance protein: identification of regions required for active transport of leukotriene C4. J Biol Chem 1998 ; 273: 10733-10740.
22. Zelcer N., Huisman MT, Reid G., Wielinga P., Breedveld P., Kuil A.,, et al. Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem 2003 ; 278: 23538-23544.
23. Huber M., Guhlmann A., Jansen PLM, Keppler D.: Hereditary defect of hepatobiliary cysteinyl leukotriene elimination in mutant rats with defective hepatic anion excretion. Hepatology 1997 ; 7: 224-228.
24. Zamek-Glyszczyinsky MJ, Xiong H., Patel NJ, Turncliff RZ, Pollack GM, Brouwer KL: Pharmacokinetics of 5 (and 6)-Carboxy-2, ′7′dichlorofluorescein and its diacetate promoiety in the liver. J Pharm Exp Ther 2003 ; 304: 801-809.
25. Pratt S., Chen V., Perry WI III, Starling JJ, Dantzig AH: Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport. Eur J Pharm Sci 2006 ; 27: 524-532.
26. Xiong H., Suzuki H., Sugiyama Y., Meier PJ, Pollack GM, Brouwer KL: Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment. Drug Metab Dispos 2002 ; 30: 962-969.
27. Bakos E., Evers R., Sinko E., Varadi A., Borst P., Sarkadi B.: Interaction of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 2000 ; 57: 760-768.
28. Szentpetery Z., Kern A., Liliom K., Sarkadi B., Varadi A., Bakos E.: The role of the conserved glycerin of ATP-binding cassette signature motifs of MRP1 in the communication between the substrate-binding site and the catalytic centers. J Biol Chem 2004 ; 279: 41670-41678.
29. Muller M., Bakos E., Welker E., Varadi A., Germann UA, Gottesman MM,, et al. Altered drug-simulated ATPase activity in mutants of the human multidrug resistance protein. J Biol Chem 1996 ; 271: 1877-1883.
30. Sarkadi B., Price EM, Boucher RC, Germann UA, Scarborough GA: Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 1992 ; 267: 4854-4858.
31. Cheng Y., Prusoff WH: Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973 ; 22: 3099-3108.
32. Akao T., Hanada M., Sakashita Y., Sato K., Morita M., Imanaka T.: Efflux of baicalin, a flavone glucuronide of Scutellariae Radix, on Caco-2 cells through multidrug resistance-associated protein 2. J Pharm Pharmacol 2007 ; 59: 87-93.
33. Horikawa M., Kato Y., Tyson CA, Sugiyama Y.: The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet 2002 ; 17: 23-33.
34. Payen L., Delugin L., Courtois A., Trinquart Y., Guillouzo A., Fardel O.: The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells. Br J Pharmacol 2001 ; 132: 778-784.
35. Leier I., Hummel-Eisenbeiss J., Cui Y., Keppler D.: ATP-dependent paraaminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int 2000 ; 57: 1636-1642.
36. Mayer R., Kartenbeck J., Buchler M., Jeditschky G., Leier I., Keppler D.: Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J Cell Biol 1995 ; 131: 137-150.
37. Ishikawa T., Muller M., Klunemann C., Schaub T., Keppler D.: ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. role of the ATP-dependent transport system for glutathione S-conjugates. J Biol Chem 1990 ; 265: 19279-19286.
38. Mayatepek E., Lehmann WD: Defective hepatobiliary leukotriene elimination in patients with the Dubin-Johnson syndrome. Clin Chim Acta 1996 ; 249: 37-46.
39. Cui Y., Konig J., Buchholz U., Spring H., Leier I., Keppler D.: Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999: 55: 929-937.